DNA Synthesis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035

The Global DNA Synthesis Market was valued at USD 2.5 billion in 2025 and is estimated to grow at a CAGR of 16.3% to reach USD 11.5 billion by 2035.

The market is experiencing strong momentum due to rising demand for synthetic DNA across molecular biology, synthetic biology, genetic engineering, and clinical diagnostics applications. Increasing prevalence of genetic and chronic diseases is further strengthening the need for advanced research in drug discovery, vaccine development, and personalized medicine. Expanding biotechnology investments, growing adoption of high-throughput synthesis platforms, and continuous technological improvements in genomics are further supporting industry expansion. In addition, the availability of advanced commercial synthesis services and rising integration of DNA-based research tools in life sciences are accelerating global adoption. The market is also benefiting from increasing collaboration between biotechnology firms, pharmaceutical companies, and research institutions focused on developing next-generation genetic solutions. Growing emphasis on precision medicine and engineered biological systems is further reinforcing long-term demand, while automation and digitalization in synthesis workflows are improving scalability, speed, and accuracy across applications.

DNA synthesis is defined as the laboratory-based creation of artificial DNA sequences using chemical or enzymatic techniques. This process enables the precise construction of customized genetic material used in a wide range of applications such as gene editing, therapeutic development, molecular diagnostics, vaccine research, and synthetic biology. It plays a foundational role in modern biotechnology by supporting the design of engineered genes, biological pathways, and complex living systems for both commercial and research purposes. The technology is increasingly integrated into advanced biological engineering workflows, enabling faster experimentation and innovation across life sciences industries.

The oligonucleotide synthesis segment is projected to grow at a CAGR of 16% during 2026-2035. Its dominance is mainly supported by strong utilization in PCR, qPCR, gene sequencing, cloning, and gene-editing applications. These short DNA fragments are widely used as essential laboratory consumables in both clinical and research environments, creating steady and recurring demand. Ongoing product innovations and strategic partnerships among industry participants are further strengthening segment growth.

The academic and research institutes segment accounted for a share of 54.5% in 2025. This leadership is driven by extensive use of synthetic DNA in genomics research, molecular cloning, functional biology studies, pathway engineering, and broader life science investigations. Consistent funding support from public and private organizations for universities, government laboratories, and research centers continues to sustain strong demand for oligonucleotide and gene synthesis services across scientific disciplines.

North America DNA Synthesis Market held a 38.7% share in 2025. The region's dominance is supported by significant investments in biotechnology and genomics research, along with the presence of leading DNA synthesis companies and highly advanced research infrastructure. Strong government support, along with collaborations between industry participants and research organizations, is further driving growth. The region benefits from a mature biotechnology ecosystem that includes pharmaceutical companies, synthetic biology developers, contract research organizations, and academic institutions actively utilizing high-throughput DNA synthesis technologies for drug discovery and advanced research applications.

Prominent players operating in the Global DNA synthesis industry include GenScript Biotech, Thermo Fisher Scientific, Eurofins Scientific, Integrated DNA Technologies, Twist Bioscience, BIOMATIK, Bioneer, Eton Bioscience, IBA Lifesciences, Kaneka Eurogentec, LGC Biosearch Technologies, OriGene Technologies, ProMab Biotechnologies, ProteoGenix, Quintara Biosciences, Shenzhen Shuxin Biotechnology, Synbio Technologies, and LGC Biosearch Technologies. Companies operating in the DNA synthesis market are increasingly focusing on technological innovation, automation, and scalability to strengthen their market position. A key strategy includes expanding high-throughput synthesis capabilities to meet rising demand from research and pharmaceutical applications. Market players are heavily investing in next-generation synthesis platforms that improve speed, accuracy, and cost efficiency. Strategic collaborations with biotechnology firms, academic institutes, and pharmaceutical companies are also enhancing product development and application reach. Many companies are strengthening their global distribution networks and expanding service portfolios to include customized DNA design and rapid delivery solutions.